Scientific poster: Evaluating compound binding and MoA with human iPSC-derived atrial cardiomyocytes
This scientific poster describes how we supported target identification and confirmed mechanism of action with Ncardia's human iPSC-derived models and screening services
TAKE THE FIRST STEP
![FDRA](https://www.ncardia.com/hs-fs/hubfs/FDRA.png?width=620&height=887&name=FDRA.png)
ABOUT US
Predict future safety and efficacy more efficiently
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas.